

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era
Tweetorial #3 References

Tweet 7

Giovannoni G, Lang S, Wolff R, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. *Neurol Ther.* 2020;9(2):359-374.

Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. *Am J Med.* 2020;133(12):1380-1390.e1382.

Lucchetta RC, Tonin FS, Borba HHL, et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. *CNS Drugs.* 2018;32(9):813-826.

Tweet 8

Aubagio. [full prescribing information]. 2012.

Avonex. [full prescribing information]. 2012.

Bafiertam [full prescribing information]. 2020.

Betaseron. [full prescribing information]. 1993.

Copaxone [full prescribing information]. 2016.

Gilenya [full prescribing information]. 2019.

Mavenclad [full prescribing information]. 2019.

Mayzent [full prescribing information]. 2021.

Plegridy [full prescribing information]. 2020.

Tecfidera [full prescribing information]. 2013.

Vumerity [full prescribing information]. 2019.

Zeposia [full prescribing information]. 2021.

Tweet 9

Kesimpta [full prescribing information]. 2020.

Lemtrada [full prescribing information]. 2021.

Ocrevus [full prescribing information]. 2017.

Tsybari [full prescribing information]. 2020.

Tweet 12

Steinman L, Fox E, Hartung H-P, et al. Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: results of the Phase 3 ULTIMATE I and II trials. 2021 AAN Annual Meeting, April 17-22. Poster 9056.

Tweet 13

Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy? *J Neuroimmunol*. 2002;131(1-2):5-20.

Tweet 15

Vermersch P, Hermine O. Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002. ACTRIMS/ECTRIMS MSVirtual 2020. *Mult Scler J*. 2020;26(S3):9-42.

Tweet 17

Kolahdouzan M, Futhey NC, Kieran NW, Healy LM. Novel molecular leads for the prevention of damage and the promotion of repair in neuroimmunological disease. *Front Immunol*. 2019;10:1657.

Roach CA, Cross AH. Anti-CD20 B cell treatment for relapsing multiple sclerosis. *Front Neurol*. 2020;11:595547.

Tweet 18

Montalban X, Arnold DL, Weber MS, et al. Placebo-controlled trial of an oral btk inhibitor in multiple sclerosis. *N Engl J Med*. 2019;380(25):2406-2417.

Glossary

5-HT, 5-hydroxytryptamine
AE, adverse event
ALT, alanine aminotransferase
APC, antigen-presenting cell
Approx, approximately
ARR, annualized relapse rate
ATP, adenosine triphosphate
BBB, blood-brain barrier
BBW, black box warning
BC, B cell
BID, bis in die (twice a day)
BTK, Bruton's tyrosine kinase
CD20, B-lymphocyte antigen
CD52, cluster of differentiation 52
CDI, clinical documentation improvement
CDP, confirmed disability progression
CDW, confirmed disability worsening
CI, confidence interval
C-kit, tyrosine kinase receptor CD117
CNS, central nervous system
CSF, cerebrospinal fluid
DMF, dimethyl fumarate
DMT, disease-modifying therapy
DRF, diroximel fumarate
Dz, disease
EDSS, Expanded Disability Status Scale
EVO, evobrutinib
GA, glatiramer acetate
Gd, gadolinium
GI, gastrointestinal
H2H, head-to-head
HR, hazard ratio
HTN, hypertension
IFNbeta-1a, interferon beta-1a
IFNbeta-1b, interferon beta-1b
IV, intravenous
LRTI, lower respiratory tract infection
LSM, least squares mean
MAS, masitinib
MOA, mechanism of action
MMF, mycophenolate mofetil
MRI, magnetic resonance image
MS, multiple sclerosis
NAA, nucleic acid amplification
NEDA, no evidence of disease activity
NO, nitric oxide

NP, nurse practitioner
Nrf2, nuclear factor erythroid 2
nSPMS, nonactive secondary-progressive multiple sclerosis
NSS, not statistically significant
PA, Physician assistant
PBO, placebo
Peg INFbeta-1a, pegylated interferon beta-1a
Ph2, phase two
Ph3, phase three
Pharm, pharmacist
PML, progressive multifocal leukoencephalopathy
PPMS, primary progressive MS
Pt, patient
QD, quaque die (once a day)
RN, registered nurse
RMS, relapsing forms of multiple sclerosis
RRMS, relapsing-remitting multiple sclerosis
RTK, receptor tyrosine kinase
S1PR, sphingosine 1-phosphate receptor
SCF, stem cell factor
SPMS, secondary-progressive multiple sclerosis
T1, T1-weighted MRI sequence
T2, T2-weighted MRI sequence
TEAE, treatment-emergent adverse events
TER, teriflunomide
TNF-a, tumor necrosis factor alpha
Tx, treatment
URTI, upper respiratory tract infection
UTI, urinary tract infection
W, week
w/, with